Novo Nordisk continues diabetes, obesity sales rise, but still on the back foot with Wegovy supply
As demand for Novo Nordisk’s GLP-1 products continues unabated, all eyes are on the pharma giant to meet demand.
Starting this month, Novo has more than doubled its starter doses for Wegovy in the US, which could be reflected in script numbers over the next few weeks, CEO Lars Fruergaard Jørgensen said on a media call Wednesday morning. The company began restricting starter doses in May.
But supply remains unsteady, as Wegovy supply issues continue due to unwavering demand. According to the FDA, it is still in shortage in the US. “It’s probably to be expected that for quite some time. There’ll be a demand that outgrows what can be produced by us and probably also competition,” Jørgensen said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.